The Certificate released by Carbon Trust that has calculated the CO2 emissions for all our products.This is the first t

EMA has endorsed two statements about the importance, safety and effectiveness of vaccines published today by the International Coalition of Medicines Regulatory Authorities (ICMRA). International regulators from around the world have come together and jointly developed these statements for healthcare professionals and the general public to give assurance that the regulatory processes for the authorisation and safety monitoring of vaccines are robust, independent and focus firmly on public health. ‘The COVID-19 health emergency reminds us how important vaccines are to protect ourselves and our loved ones against infectious diseases,’ said Guido Rasi, Chair of ICMRA and EMA’s Executive Director. ‘In fact, vaccines are that one medical intervention that benefits not only those who receive it directly but also those who are too young, too old or too ill to be vaccinated themselves.’ The two ICMRA statements aim to reassure healthcare professionals and the public around the globe that medicines regulators only allow vaccines onto the market that fulfil the highest standards of safety, efficacy and quality. In recent years, vaccination coverage has dropped to sometimes dangerously low levels in some countries, which increases the risk of the disease spreading and affecting the unvaccinated. The ICMRA statements reiterate that it is everyone’s responsibility to get vaccinated in order to protect not only themselves but also their friends, communities, vulnerable populations who cannot get immunised as well as the generations to come. ICMRA is an international coalition of 29 medicines regulatory authorities from every region in the world, with WHO as an observer, which works to address global regulatory challenges. Medicines regulators recognise their important role in facilitating access to safe and effective high-quality medicines that are essential to human health and well-being. This includes ensuring that the benefits of vaccines outweigh their risks. The development of the joint statements followed a series of discussions among ICMRA members on new ways to collaborate and enhance confidence in vaccine safety and effectiveness. The ICMRA statements are available in multiple languages on the ICMRA website. Contact point EMA press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

CVMP adopts a draft strategy on antimicrobials 2021-2025 CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a grouped type II variation application for Bluevac BTV8 to add the strains BTV1 and BTV4 into the vaccine. The Committee adopted by consensus a positive opinion for a type IB variation application for Stronghold Plus and Felisecto Plus (selamectin/sarolaner) to correct the translations of product information. More information about the above-mentioned medicines, including their full indication, will be published on the Agency’s website. Renewals of marketing authorisations The Committee adopted by consensus positive opinions for the renewal of the marketing authorisations for Simparica and Zycortal. The Committee, having re-assessed the benefit-risk balance of these products, concluded that the quality, safety and efficacy continue to be appropriately demonstrated and, therefore, recommended the renewal of the marketing authorisations. Community referrals and related procedures The Committee concluded the referral procedure for Dinolytic 12.5 mg/ml and 5 mg/ml solutions for injection and associated names, and generic products thereof. The matter was referred to the Committee by France under Article 35 of Directive 2001/82/EC due to concerns relating to the appropriateness of the withdrawal periods in cattle. The Committee agreed that the withdrawal periods for cattle meat and offal should be amended to provide assurance for consumer safety. The Committee adopted by consensus an opinion concluding that the marketing authorisations of the concerned products should be varied in order to amend the product information accordingly. The Committee adopted by majority a corrigendum of the opinion adopted on 20 May 2020 on the procedure under Article 45 of Regulation (EC) No. 726/2004 for Suvaxyn PRRS MLV from Zoetis Belgium SA. In the corrected opinion, a sentence was reinstated in the product information. Maximum residue limits The Committee adopted by consensus a positive opinion recommending the establishment of maximum residue limits for bupivacaine in bovine. More information about the above recommendation will be published on the Agency’s website. The Committee agreed to include natural crystalline graphite as a new entry in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009 under the heading of excipients and adopted a revised list (EMA/CVMP/519714/2009-Rev. 44). This decision followed the Committee’s review of a request that had been submitted in accordance with the relevant CVMP guidance. The document will be published on the Agency’s website. Minor use, minor species (MUMS)/limited market Following the Committee’s review of a request for classification under the MUMS/limited market policy, the CVMP classified a product (immunological) for dogs as indicated for MUMS/limited market and eligible for reduced data requirements, where applicable. The product is not eligible for financial incentives as it is intended for use in non-food producing species. The Committee also reclassified a product (systemic hormonal preparation) for horses as indicated for MUMS/limited market and eligible for reduced data requirements, when applicable. The product is not eligible for financial incentives in line with the Guidance on the classification of veterinary medicinal products indicated for minor use minor species MUMS/limited market (EMA/CVMP/388694/2014) as according to the MUMS policy, products for horses are generally not eligible for fee incentives. Pharmacovigilance The Committee reviewed the PSURs for Purevax FeLV and Vectra 3D, and recommended amendments to the product information. The Committee also reviewed the PSURs for Comfortis, Credelio, Innovax ILT, Masivet, Melovem, Nasym, Osurnia, ProZinc, Sileo, Ubac and Zactran, and concluded that no further action or changes to their product information were required. Concept papers, guidelines and SOPs Quality The Committee adopted a new guideline on water for pharmaceutical use (EMA/CHMP/CVMP/QWP/496873/2018), further to its adoption by CHMP at their May 2020 meeting. It replaces the Note for guidance on quality of water for pharmaceutical use (EMEA/CVMP/115/01). This guideline takes into account comments received during public consultation and addresses changes in some European Pharmacopoeia monographs (water for injections – revised, water for preparation of extracts – new, water highly purified – deleted) as well as current expectations for the minimum acceptable quality of water used in the manufacture of active substances and medicinal products for human and veterinary use. The document(s) above will be published on the Agency’s website. Antimicrobials The Committee adopted the draft CVMP strategy on antimicrobials 2021-2025 (EMA/CVMP/179874/2020) for a 3-month period of public consultation. In the context of this strategy, the focus of the CVMP’s activities regarding antimicrobials over the next five years will be on supporting the effective implementation of those provisions in the Regulation (EU) 2019/6 that take forward the EU’s One Health Action Plan against antimicrobial resistance (AMR). Proposed actions address measures embedding the responsible use of antimicrobials in veterinary medicine, the protection of public and animal health from the risk of AMR and support to the development of new antimicrobials and their alternatives. Immunologicals The Committee adopted questions and answers on management of extraneous agents in immunological veterinary medicinal products (EMA/CVMP/IWP/669993/2019). The Committee adopted a revised mandate, objectives and rules of procedure for the CVMP Immunologicals Working Party (EMA/CVMP/IWP/208689/2004). The questions and answers document and the revised mandate will be published on the Agency’s website. Regulatory Further to the request from the European Commission, the Committee adopted scientific recommendations for implementing measures under Article 57(4) of Regulation (EU) 2019/6 on veterinary medicinal products regarding the format of the data to be collected on antimicrobial medicinal products used in animals. The documents will be sent to the European Commission and published on the Agency’s website in due course. Contact point EMA Press office Tel. +31 (0)88 781 8427 E-mail: press@ema.europa.eu Follow us on Twitter @EMA_News

Five-year agreement makes Antares exclusive supplier of all inspection and tracking technologies, and lays groundwork for innovative jointly-developed solutions Two Italy-based equipment solutions leaders to bring digital innovation into sectors with high growth potential Travagliato (BS), June 17, 2020 – Antares Vision has entered into a partnership with IMA, a company listed in the STAR segment and a global leader in the design and production of machines for process automation and packaging of pharmaceutical and cosmetic products, foodstuffs, tea and coffee. The two companies’ 20-year history of cooperation supplying inspection systems to ensure the quality and integrity of pharmaceutical packaging will now extend to a variety of other segments – including food & beverage, cosmetics and medical devices – for product traceability and smart data management. This turns Antares Vision into one of the go-to technological partners supporting digital innovation efforts for the entire IMA Group internationally. Aimed at consolidating and strengthening the leadership of both partners in existing and emerging markets, the five-year agreement involves synergistic cooperation for developing and implementing innovative solutions via specific projects, new business opportunities and new products. These will initially take the form of new, collaborative production lines, then expanded to comprise upgrades and retrofits of existing lines. The agreement will result in significant growth in the integration of Antares Vision technology within IMA machines, further strengthening this important commercial and technological partnership. Emidio Zorzella, Chairman and Managing Director of Antares Vision: “We are extremely pleased with the agreement we have reached with our partner, with whom we have been sharing experiences and skills in the pharmaceutical sector for over 20 years, through the supply of visual inspection systems for product quality control. IMA has affirmed and strengthened its partnership with our company – the only technological player able to offer a single, comprehensive solution by integrating the supply of inspection systems with tracking and data analysis solutions along the whole production chain, thereby guaranteeing product quality and transparency. The agreement with IMA will allow us to penetrate new sectors more quickly and consistently, per our mission to bring our high-value offerings into high-leverage sectors beyond pharmaceuticals. Together, the two global leaders promote the digitisation of the supply chain, with future-ready applications, from automation, to interconnection, to smart data management, to guarantee Trustparency – transparency that generates trust.” ABOUT ANTARES VISION Listed since April 2019 on the Italian Stock Exchange in the AIM Market after a business combination with ALP.I (SPAC promoted by Mediobanca), Antares Vision guarantees the protection of products during their life cycle through visual inspection systems for quality control, Track & Trace solutions for anti-counterfeiting and supply chain control, smart data management for maximized efficiency and customer engagement, in all the most demanding industrial sectors, from pharmaceutical to biomedical devices, from food to beverage, from cosmetics to fashion. Antares Vision reaches over 60 countries in the world with complete and flexible solutions, hardware and software, and related services: four Italian branches (Brescia, Parma, Piacenza, Latina), 12 foreign branches (Ireland, Germany [2], France [2], USA [2], Brazil [2], India, Russia and Hong Kong), two Innovation Centers (Italy and Ireland) and a worldwide network of more than 30 partners. With 20 years of experience in vision technologies, Antares Vision is supplier of 10 of the 20 leading pharmaceutical Companies in the world with more than 25.000 vision systems, that ensure every day product safety and quality, 6.500 inspection checks on production lines and more than 3.500 serialization lines installed all over the world to guarantee the tracking of more than 5 billion products across the whole supply chain. With the aim of continuing and supporting the growth and development strategy, during 2019 participation agreements were finalized with T2 Software, a Brazilian company specialized in smart data management solutions, and Orobix, an Italian company leader in artificial intelligence services, as well as the acquisition of 100% of FT System, leader in control and inspection in the beverage sector. In April 2020, Antares Vision finalized an agreement for the acquisition of 82.83% of Tradeticity, a Croatian company specialized in software management of advanced traceability processes. In 2019 Emidio Zorzella and Massimo Bonardi were awarded the Ernst & Young Entrepreneur of the Year award for innovation. www.antaresvision.com

Speciality security printer Eltronis has reported a 20 per cent increase in enquiries for its brand protection and track and trace solutions since the outbreak of Coronavirus. The majority of these new enquiries have come from the pharmaceutical sector, reflecting the rise in public demand for immunity and health protection against the virus. Eltronis, which recently opened its European head office in the UK in Oxfordshire, delivers security and authentication solutions to leading global brands in the pharmaceutical, automotive, security, brand protection and industrial sectors. The significant growth in enquiries follows the recent warning from the International Hologram Manufacturers Association (IHMA), of which Eltronis is a member, about criminals profiting from the COVID-19 crisis. Its report highlighted the urgent need for more investment in anti-counterfeiting technologies. The message from the IHMA coincided with alerts about counterfeit goods from Europol and EUIPO, particularly regarding the international trade in fake pharmaceuticals, which is worth in excess of $4bn. Pete Smallwood, Business Development Manager for Eltronis, said, “Since the outbreak of Coronavirus we have seen a significant increase in the number of anti-counterfeit enquiries we have received, largely from our pharmaceutical customers. “These enquires have not only come from our traditional markets but also from further afield, with projects throughout Europe, the Middle East and a number of specific requests in Indonesia and the Far East.” Eltronis technologies and products enable consumers to carry out a quick and trusted authentication check, while also ensuring a significant deterrent to counterfeiters. The patented solutions can be integrated into a range of label and packaging applications and combine with other technologies such as Eltronis’ in-house track and trace system. This not only allows customers to quickly and easily check that their goods are genuine, but also gives brands the opportunity for greater consumer engagement. In addition, bespoke software development can help detect grey imports across markets, providing multi-layered functionality from one product. “Counterfeit goods generally do not meet the required quality standards and pose a real threat to public health, particularly during this pandemic,” said Pete. “People who buy these fake products are given a false sense of security, when in fact they are left unprotected against the virus, as well as being at potential risk from the contents of the fake medicines. “Having an effective brand protection strategy is now an essential part of today’s medicines and pharmaceutical goods, ensuring they meet all legislative requirements, as well as enabling examiners and consumers to clearly verify the authenticity of the products in the market and protect themselves from fakes.” Ends ABOUT ELTRONIS Founded in 2003, Eltronis is a privately owned speciality security printer which has established itself as a trusted partner for a wide range of global brand owners, pharmaceutical suppliers and automotive manufacturers alongside its various long-standing governmental projects. Headquartered in the UK and with manufacturing in Eastern Europe, Eltronis combines all forms of traditional security print with digital and holographic technologies. By identifying the key issues faced by each customer, the business ensures its unique and often patented solutions meet the specific needs of each project. As an established supplier of security solutions for governments worldwide, Eltronis offers a single source supply for security documents such national IDs, voter programmes, tax stamps and driving licences. Production is within a guarded and patrolled environment with full access control, CCTV, secure storage and waste destruction. Eltronis is ISO certified for Quality, Environmental and Health and Safety and is a member of the IHMA. Visit online at www.eltronis.com For Eltronis sales enquiries please contact: Pete Smallwood, Business Development Manager Tel: +44 (0) 1473 356544 Email: pete.smallwood@eltronis.com For Eltronis media enquiries please contact: Simon Wildash or Phil Stubbs, Nielsen McAllister Tel: +44 (0)1332 293939 Email: info@nmpr.co.uk

Today, edible oil is a very competitive market category, essentially driven by product and brand differentiation as well as competitiveness through packaging cost savings, production efficiency and permanent asset optimisation. Sidel, as a leading solution provider, have a strong heritage in edible oil, acting as a one-stop shop partner in proposing complete and integrated PET lines. The company’s strength is also based on their comprehensive portfolio of equipment capable of answering any request in terms of PET bottles, labels, caps, secondary packaging, footprint and line speeds along with ensuring an overall technical coherence, an adapted level of investment and an optimized return on investment (ROI). Currently, a number of trends are strongly shaping the production environment of edible oil producers: product diversification and tough competition, asking for cost savings, are driving the industry. “Product diversification is bringing more product shapes, sizes and SKUs to handle for the producers, therefore, the need for more flexible lines and equipment is rising,” says Francesca Bellucci, Marketing Director for the Food, Home & Personal care market categories at Sidel, “regardless, whether we are talking about capital expenditures (CAPEX), operating expenses (OPEX) or total cost of ownership (TCO), all that nowadays matters to edible oil producers.” Sidel’s 40-year heritage in PET packaging, coupled with the company’s cutting-edge equipment, prove to be instrumental in helping producers active in this market segment to step up quickly. Sidel are able to provide edible oil producers with assistance very early in the value chain with engineering services for the line design and packaging design capabilities. “Built into our very roots, our holistic approach to the edible oil industry contributes to delivering the right level of performance our customers need. At Sidel, we genuinely believe that achieving optimum quality and safety levels while lowering costs and optimising assets along the line lifecycle is most easily achieved with a one-stop shop partner,” explains Francesca Bellucci. Secured performance and TCO with coherent complete line solutions Being a global solution provider for complete and integrated lines, Sidel are capable of adapting each and every component of the line to perfectly fulfil edible oil producers’ expectations or specific needs. Industrial turnkey line solutions with in-line PET bottle blowing are a promising approach to boost edible oil producers’ productivity from the beginning to the end of the line due to a coherent process and flow management. A great example is Sidel’s partnership with B.L. Agro Industries Ltd., an Indian-based manufacturer of edible oils, for which Sidel have successfully provided over the past five years, three different lines with different approaches, challenges and objectives to bottle sizes, shapes, secondary packaging and line speed. “Sidel greatly supported us along the whole journey,” says Ashish Khandelwal, Executive Director at B.L. Agro. “Relying on a single supplier who takes the full line responsibility including packaging, was a great help, especially because whatever we produce must adhere to the highest quality standards,” he adds. For Sidel as well as for B.L. Agro, line control and automation are at the heart of the system, ensuring the continuous running and the overall performance of the line. “In terms of efficiency, we are now reaching 98.5% on our first line, running at 24,000 bottles per hour (bph) with our small format bottles and 97.6% on our second one at 6,000 bph for the big containers. Our third line is currently being ramped up, but we fully trust to achieve efficiency up to 90% in two or three weeks’ time,” explains Ashish Khandelwal. Single supplier with large portfolio adapted for every need Sidel have a deep knowledge at each step of the line with leading-edge equipment and state of the art technology. On the wet part of the line, capabilities in blowing, filling, capping and labelling have to be available for every need or speed to address the various market demands. This has also been the case for B.L. Agro over the past years: From stand-alone blowers being able to manage small bottles at high speed or large bottles with the creation of notches for the insertion of a handle, up to Combi blowing, filling and capping solutions to reduce space and minimize the risk of cross-contamination, Sidel have really expressed the breadth of their blowing capability at B.L. Agro packaging facility. Sidel’s portfolio also guarantees various options for labellers, supporting wrap around or pressure sensitive labels as well as bottle/pack/pallet conveyors and accumulation tables. End-of-Line solutions: Flexibility at all levels The End-of-Line solutions, i.e. the packing, shrink-wrapping and palletising solutions, are also a critical part of the complete line, especially when it comes to SKU multiplication and the flexibility required to pack them. “For our 200 ml, 500 ml, and 1 L bottles, we use American boxes (RSC), while for our 2 L and 5 L bottles, we use Wrap-Around blanks,” explains Ashish Khandelwal. Sidel have been able to install a case erector, a vertical robotic packer and a case gluer, answering the need of RSC, while for the two other lines with two drastically different levels of speed, B.L. Agro chose Cermex WB46 intermittent case packer for the low speed line and VersaWrap® continuous packer for the most recent high speed line. Equally significant next to answering the operational needs with the right level of technology, Sidel have been able to adapt and support B.L. Agro with the expected level of investment or CAPEX. “We are happy to have found a complete line solution under one roof. Our production costs have been drastically reduced. Perhaps we are one of the most efficient in the industry in terms of hygiene as well as operational efficiency,” concludes Ashish Khandelwal. Further details on Sidel’s complete line solutions for edible oil are available at https://www.sidel.com/en/home-personal-care-pharma-ca-7. Editors Note: The images within this document are for illustrative purposes only and should not be used for reproduction. If high resolution copies are not attached with the document, please contact Nikolaus Schreck at F&H Porter Novelli for copies – see contact details below. ----------------------------------- For editorial, advertising and sponsorship enquiries, please contact: F&H Porter Novelli Nikolaus Schreck, Senior Consultant Tel: +49 (0) 89 12175-123 Email: sidel@fundh.de

The tumultuous days and the events that have unfolded across the United States and have reverberated around the world,

Patients suffering from life-threatening allergies always carry a life-saving companion with them: an adrenaline autoinjector in order to immediately inject themselves in the event of an anaphylactic shock and to thus counter an allergic reaction. For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an Autoinjector-Label with special protection against abrasion. Thus, the vital user and product information remains perfectly legible over an extended period of time. The label won an award in the 2019 TLMI Competition. Epinephrine is a prescription drug for the treatment of life-threatening allergic emergencies. TEVA, a worldwide leader in generic drugs and specialty medicines, offers the adrenaline in single-dose, prefilled disposable autoinjectors. The label developed by Schreiner MediPharm for this injector is provided with abrasion- and scratch-resistant reverse printing. As a result, it is particularly resistant against chemical and mechanical impacts it is exposed to while the autoinjector is being carried in a purse or backpack, for instance. Due to its special material construction and design that is precisely adapted to the sophisticated shape of the autoinjector, the marking label securely adheres to the device. Thus, the vital information about the product and its use is reliably legible and readily available at all times. An additional cover protecting the label against abrasion or separation is not necessary, which reduces waste and the environmental footprint. For product and patient safety, the label features a perforation that clearly and irreversibly indicates any first opening of the cap and thus any potential tampering attempt. The TEVA Autoinjector-Label won recognition in the yearly North American Tag and Label Manufacturers Institute (TLMI) Competition that awarded Schreiner MediPharm’s product development with second place in the “Multi-Process” category in 2019. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com For additional information, contact: Schreiner MediPharm, a business unit of Schreiner Group GmbH & Co. KG Bruckmannring 22 85764 Oberschleissheim Germany Phone +49 89 31584-5400 Fax +49 89 31584-5422 info@schreiner-medipharm.com www.schreiner-medipharm.com

The motor is the centerpiece of an e-bike. The belt drive from Brose Antriebstechnik features an extremely quiet, robust and low-maintenance design and makes for a feeling of natural riding. The belt is installed in a protective housing. For reliable proof of the most recent maintenance, Schreiner ProTech developed a tamper-evident label with first-opening indication for Brose Antriebstechnik modified to suit the customer’s needs and the application. The label reliably indicates any unauthorized opening of the housing and thus potential tampering attempts. During scheduled servicing it is important for the shop to see if the most recent maintenance was expertly performed and that the belt has not been tampered with since then. A label from Schreiner ProTech modified to suit the customer’s needs and the application guarantees this. Special die cuts will destroy the label in an attempt to remove it and indicate any unauthorized opening of the housing, thus protecting the manufacturer and bike retailers against unjustified warranty claims. The development posed the challenge of modifying a basic label for permanent adhesion to the powder-coated surface of the drive housing and destruction in a peel-off attempt. The font and color of the label match Brose Antriebstechnik’s corporate design. “Together with Schreiner ProTech we developed a label that fully meets the requirements for our premium e-bike drives in terms of high-grade appeal, quality and technical design,” says Holger Pries, Head of Development Brose Antriebstechnik. The label optimally ensures and documents that the drive has exclusively been serviced in a professional manner or is in original condition. For more information, please contact: Eva Manzenreiter, Product Communication Phone +49 89 31584-5517, eva.manzenreiter@schreiner-group.com

As the new and preferred sales partner for Varcotec's innovative Lock 3 technology, Siegwerk is expanding its range of packaging inks and varnishes with a unique antimicrobial dispersion varnish suitable for a wide range of applications and packaging types. Siegburg, 16. June 2020. – Siegwerk, one of the leading suppliers of printing inks for packaging applications and labels, and Varcotec, a specialist for technically sophisticated overprint varnishes made for the printing industry, have entered into a distribution partnership for Varcotec's Lock 3 antimicrobial coating technology in the EMEA region (Europe, Middle East and Africa). This innovative dispersion varnish is the first of its kind, and was developed in cooperation with a spin-off company affiliated with the University of Regensburg, Germany. The antimicrobial effectiveness of this product has already been confirmed by several independent testing institutions. “With the integration of Varcotec's innovative product technology, we are adding a unique solution for various applications and packaging industries to our portfolio, thereby once again reinforcing the holistic nature of our offers for the packaging market,” said Hanns Martin Kaiser, Vice President Paper & Board EMEA and Liquid Food Packaging at Siegwerk. Even if printed surfaces on packaging generally do not constitute a hazard, consumers continue to be exposed to potentially contaminated surfaces. As different germs (e.g. viruses, bacteria, fungi) exhibit varying survival times, the Lock 3 technology makes a valuable contribution to avoid risks of transmitting bacterial and viral infections when products’ printed surfaces (outer packaging, partitions, exercise books, etc.) are handled by multiple people in short time. Lock 3 antimicrobial solutions help to provide extra security in a multitude of applications by interrupting chains of infection early on. “With Lock 3, Varcotec has launched the first antimicrobial dispersion varnish based on the principle of photodynamics in order to reliably reduce the germ loads,” added Paul Pain, Global Head of Water-based Technology at Siegwerk. “We are pleased to be able to include this unique product innovation in our portfolio, allowing us to offer this to our customers as partner of Varcotec." According to scientific data, germs can survive on surfaces from a few hours up to several months. “Until now, it has not been possible to apply a reliable coating onto absorbent substances, such as paper and cardboard, which would continuously and permanently destroy those germs,” explains Joachim Frings, from Sales and Development at Varcotec. “With Lock 3 we have succeeded in developing a varnish system which can demonstrably reduce the germ load on a wide range of printed products, already at ambient lighting conditions.” The water-based overprint varnish Lock 3 allows for permanent, independent disinfection of the printed surfaces under ambient room lighting or in open daylight. Lock 3 contains a specially patented substance, taking advantage of the principle of photodynamics: the photocatalyst is activated by visible light and transfers the energy thus absorbing the surrounding oxygen. This process creates so-called singlet oxygen, efficiently killing germs by oxidizing their shells. For more than 20 years, singlet oxygen has been used routinely in medicine for the treatment of tumors and degenerative diseases. Antimicrobial use of singlet oxygen was confirmed during this time period. No resistance develops against singlet oxygen, in contrast to what is usually observed with antibiotics and conventional biocides. The active oxygen is gaseous: It can easily reach and kill microorganisms on dry and damp surfaces. With a range of about 1 mm it reaches far enough to destroy surface microorganisms, but remains constrained from arbitrary release into the environment. The effectiveness of this varnish was already validated by several independent testing institutions. Tests have shown that Lock 3 varnishes can kill both bacteria (according to ISO 22196 (mod.) for paper and cardboard) and infectious viral particulates (based on ISO 21702 (mod.)) by more than 99%. Additional tests against other virus strains, including three members of the Coronavirus family, are currently in the testing phase. Lock 3 can already be applied to paper and cardboard by means of all commonly used printing machinery and coating equipment. The first pilot applications on plastic films are already underway, an expansion of the application range is under development and subjected to the required testing. This varnish is currently the only fully effective antimicrobial technology on the market which functions independent of moisture and temperature conditions and remains effective on dry surfaces. The photodynamic effect is temporarily suspended in darkness, but reactivated immediately upon renewed exposure to light. This varnish remains effective for up to three years. In contrast, other comparable technologies, such as coatings containing silver and copper, require the presence of moisture or even UV radiation to obtain a sufficient effectiveness for disinfection. Lock 3 dispersion varnishes are free from heavy metals, odorless and without impact on the recycling process of respective products or packaging. “We are very pleased to have gained a leading player in the printing ink and packaging industry such as Siegwerk as our partner, able to integrate our unique and innovative coating technology into a significantly larger and international sales structure, in order to increase the product’s market exposure,” added Jens Frings, Managing Director of Varcotec. Within the framework of this partnership, Siegwerk will commence marketing Varcotec's Lock 3 products in the EMEA region starting in June 2020. These products will first be available in Germany, then gradually launched in Central Europe with all countries in EMEA serviced by end of this year. The production of these varnish coating systems is still the responsibility of Varcotec. In the beginning, the product portfolio will only consist of water-based solutions. At the same time, the partners remain open to advancement of joint development activities in other areas of application, coating technologies and market regions at a later date. About Siegwerk Siegwerk, a family company in its sixth generation, is one of the world’s leading manufacturers of printing inks and individual solutions for packaging, labels and catalogs. With more than 180 years of experience, the company has in- depth knowledge and expertise of many printing processes. A global production and service provider network provides customers with products and services of consistently high quality. True to the company philosophy of “Ink, Heart & Soul,” Siegwerk strives for a long-term cooperation with its business partners. Siegwerk employs around 5,000 people worldwide in more than 30 foreign subsidiaries and is headquartered in Siegburg, near Cologne. You can find more information on Siegwerk at www.siegwerk.com About Varcotec Varcotec GmbH is a specialist in the development and manufacture of ecologically high-quality and economically efficient system solutions for the printing industry. The company's future-oriented product range includes innovative and technologically sophisticated varnish coatings of the dispersion, oil pressure, HUV, LE, LED, and conventional UV type, tailor-made for the individual needs of each of its customers. Varcotec believes the use of energy-saving and emissions-reducing materials in the printing process must be a priority in research and product development at the company. When developing new products, the company also works closely with independent testing institutions, thereby enabling achievement of the highest quality standards. Further information on Varcotec can be found at www.varcotec.de Media contact: Siegwerk: Dr. Bettina Horenburg Director Corporate Communications Tel.: +49 2241 304-732 Email: bettina.horenburg@siegwerk.com

Company inaugurates segregated 7,000-sq-ft space with a new back-number system and its third 100% inspection platform. Lakewood, NJ – Luminer, a labeling solutions provider specializing in extended content labels (ECLs) for pharmaceutical ethical and OTC packaging, clinical trials and various other narrow web applications for the cosmetics, F&B and chemicals sectors, has streamlined its precision product inspection capabilities by introducing a dedicated 7,000-square-foot inspection suite at its primary manufacturing facility in Lakewood, NJ. The quality management segregation also comes with an infrastructure investment: the company has added its third 100% inspection platform, as well as a back-number validation system. The dedicated space will further improve Luminer’s comprehensive quality management processes. In particular, it is designed to optimize QA/QC oversight for the company’s specialty, extended content labels. Due to their inherently stacked, page-over-page nature, ECLs pose unique inspection challenges requiring niche-specific solutions. Luminer provides 100% label inspection – a must for its broad set of pharma customers. For ECLs, this entails a complex process that involves, among other extra steps, precision vision systems inspecting individual sheets prior to folding, glue line monitoring to ensure all ECL pages are affixed properly and in correct order, and final inspection initiatives such as thickness monitoring to confirm label-on-label mounting veracity. Luminer’s addition of a back-number validation system provides additional assurance for pharma customers, by helping to ensure labels are matched to their proper individual packages. Among other benefits, this helps simplify the label application process and, for prescription products, lends to easier compliance with unit-level serialization requirements. “The new inspection suite helps reinforce Luminer as a medium-sized label manufacturer with big-shop production and quality control capabilities,” said Tom Spina, President & CEO of Luminer. “Extended content labels especially demand a thorough, multi-step inspection process. The dedicated quality management space and new infrastructure will further streamline our workflow, expediting turnaround time from initial quote to production to delivery.” Luminer recently incorporated a new extended content label production line, a seven-figure investment that doubled its ECL manufacturing capacity. The new line’s exemplary production speeds foster both efficiency and cost-effectiveness, ROIs that Luminer will be able to pass on to customers. # # # About Luminer Since 1989, Luminer has specialized in combining adhesive coating technology with narrow web flexographic printing and converting expertise. The company is a leader in several industry niches, chief among them extended content labels (ECLs) for clinical trial and other pharmaceutical applications. In addition, Luminer is a prominent provider of on-pack/in-pack promotional products, cosmetic and fragrance sampling devices and pressure-sensitive adhesive coated products. The company also serves the food & beverage and chemicals sector with a wide variety of labeling solutions. Located in Lakewood, NJ and Red Lion, PA, Luminer’s two facilities are each ISO 9001:2015 certified, operate under cGMP guidelines, and regularly undergo audits from high-profile pharmaceutical, cosmetics and health & beauty aid clients. For more information, call (732) 365-3673 or visit www.luminer.com. client: Luminer contact: Christopher Dale Turchette Agency (973) 227-8080, ext. 116 cdale@turchette.com Dan Goldstein Luminer (732) 886-6557, ext. 114 dgoldstein@luminer.com